Journal: Molecular Therapy. Nucleic Acids

Article Title: Reverse-phase chromatography removes double-stranded RNA, fragments, and residual template to decrease immunogenicity and increase cell potency of mRNA and saRNA

doi: 10.1016/j.omtn.2025.102491

Figure Lengend Snippet: Ion-pair reverse-phase polishing of mRNA on CIMmultus SDVB with linear gradient removes dsRNA and truncated RNA (A) A mass of 0.5 mg of Oligo dT pre-purified mRNA (eGFP) was loaded onto 1 mL CIMmultus SDVB column at room temperature and eluted in linear gradient from 7.5% to 18% ACN over 95 CV at 1 CV/min. (B) Fragment Analyzer electropherograms of selected fractions show lower molecular weight (MW) impurities eluting in fractions 1 and 2, with higher MW impurities observable in fractions 5–7 and significant in fraction 11. LM: Low molecular weight marker. (C) Elution fractions were analyzed on J2 dot blot, which confirmed the presence of dsRNA sub-populations in fractions 1, 2, 12, and strip.

Article Snippet: E. coli cell pellet containing plasmid encoding mRNA eGFP (size 995 nt) was provided by Biomay AG and plasmid for saRNA mCHIK(S27) encoding chikungunya replicase and firefly luciferase (size 9787 nt) was provided by TRON (Mainz, Germany).

Techniques: Purification, Molecular Weight, Marker, Dot Blot, Stripping Membranes

Journal: Molecular Therapy. Nucleic Acids

Article Title: Reverse-phase chromatography removes double-stranded RNA, fragments, and residual template to decrease immunogenicity and increase cell potency of mRNA and saRNA

doi: 10.1016/j.omtn.2025.102491

Figure Lengend Snippet: Analytical characterization of RNA fractions collected from SDVB linear gradient purification A mass of 0.5 mg of ARCA-capped mRNA eGFP, pre-purified with CIM Oligo dT, was loaded onto CIM SDVB column at room temperature and eluted in a linear gradient (from 7.5% to 18% ACN over 95 CV) at 1 CV/min. The first 10 mL of elution peak was collected in 20 fractions (1-20), and the remaining 30 mL was collected as one fraction (21). (A) Fragment Analyzer results show RNA size distribution in fractionated elution peak. LM: molecular weight marker. (B) Capping efficiency analysis of selected elution fractions. (C) CIMac Oligo dT chromatographic analysis indicates % polyadenylation of elution fractions. Relative amounts of unbound, non-specifically bound, and bound RNA are presented in the bar chart, from integration of CIMac Oligo dT flow-through (FT), wash (W), and elution (E) peaks, respectively.

Article Snippet: E. coli cell pellet containing plasmid encoding mRNA eGFP (size 995 nt) was provided by Biomay AG and plasmid for saRNA mCHIK(S27) encoding chikungunya replicase and firefly luciferase (size 9787 nt) was provided by TRON (Mainz, Germany).

Techniques: Purification, Molecular Weight, Marker

Journal: Molecular Therapy. Nucleic Acids

Article Title: Reverse-phase chromatography removes double-stranded RNA, fragments, and residual template to decrease immunogenicity and increase cell potency of mRNA and saRNA

doi: 10.1016/j.omtn.2025.102491

Figure Lengend Snippet: Ion-pair reverse-phase polishing of mRNA with CIMmultus SDVB operated with step elution removes dsRNA, truncated RNA, and residual pDNA template at least to 80-mL column scale Purification of (A.i) 0.6 mg and (B.i) 4.8 mg of Oligo dT-prepurified mRNA eGFP on 1 mL and 8 mL CIMmultus SDVB column, respectively, at room temperature and at 1 CV/min. Step elutions of 8.5% ACN, 11.7% ACN, and 18% ACN were applied. (A.ii and B.ii) Fragment Analyzer results of corresponding fractions. (A.iii and B.iii) J2 dot blot confirmed clearance of truncated sequences and dsRNA species in main mRNA fractions (“2”). (C.i) Scale-up preparative chromatogram of Oligo dT-prepurified mRNA (48 mg) on 80 mL CIMmultus SDVB column at room temperature and at 2 CV/min operated with Hipersep Flowdrive Pilot HPLC chromatography system. Step elutions were fractionated in five fractions (1–4 and strip). (C.ii) Fragment Analyzer and (C.iii) J2 dot blot analytics of collected fractions. (C.iv) AGE residual DNA template analysis and (C.v) CIMac pDNA quantification of residual DNA template in collected fractions.

Article Snippet: E. coli cell pellet containing plasmid encoding mRNA eGFP (size 995 nt) was provided by Biomay AG and plasmid for saRNA mCHIK(S27) encoding chikungunya replicase and firefly luciferase (size 9787 nt) was provided by TRON (Mainz, Germany).

Techniques: Purification, Dot Blot, Chromatography, Stripping Membranes

Journal: Molecular Therapy. Nucleic Acids

Article Title: Reverse-phase chromatography removes double-stranded RNA, fragments, and residual template to decrease immunogenicity and increase cell potency of mRNA and saRNA

doi: 10.1016/j.omtn.2025.102491

Figure Lengend Snippet: mRNA polishing to remove dsRNA performed with CIM SDVB spin (0.1 mL) column in a benchtop centrifuge (A) A mass of 95 μg of Oligo dT-prepurified mRNA eGFP was diluted 10 times in loading buffer containing 7.5% ACN and applied onto a CIM SDVB spin (0.1 mL) column. Wash with 8.5% ACN eluted truncated species (fraction 1), elution with 11.7% ACN yielded full-length RNA (fraction 2) and strip with 18% ACN eluted dsRNA (strip). Recovery of mRNA in fraction 2 was 77%. (B) Fragment Analyzer of load, fractions 1, 2, and strip. (C) J2 dot blot of collected fractions.

Article Snippet: E. coli cell pellet containing plasmid encoding mRNA eGFP (size 995 nt) was provided by Biomay AG and plasmid for saRNA mCHIK(S27) encoding chikungunya replicase and firefly luciferase (size 9787 nt) was provided by TRON (Mainz, Germany).

Techniques: Stripping Membranes, Dot Blot

Journal: Molecular Therapy. Nucleic Acids

Article Title: Reverse-phase chromatography removes double-stranded RNA, fragments, and residual template to decrease immunogenicity and increase cell potency of mRNA and saRNA

doi: 10.1016/j.omtn.2025.102491

Figure Lengend Snippet: Purification of mRNA and saRNA with CIM SDVB does not compromise functionality in immuno-incompetent BHK-21 cells (A) A mass of 100 ng mRNA purified with Oligo dT (“w/o SDVB”) or Oligo dT + SDVB with linear gradient elution strategy (“linear-SDVB”) or Oligo dT + SDVB with step elution strategy (“step-SDVB”) was transfected into BHK-21 cells. After 24 h, GFP expression was measured by flow cytometry. The mean fluorescence intensity was multiplied with the percentage of GFP expressing cells to receive the total GFP expression levels. (B) Relative viability of cells was assessed by measuring viability after 48 h and normalized to the mock control. (C) BHK-21 cells were lipofected with the indicated doses of either Swiper (“w/o SDVB”) or Swiper and SDVB-purified saRNA (“+SDVB”). Luciferase expression was measured 6, 24, 48, and 72 h after transfection. Area under the curve (AUC) was calculated to determine the total luciferase expression. (D) Viability was measured 48 h after transfection and normalized to the mock control. Mean and standard error of the mean (SEM) of three independent experiments, each performed in technical triplicates, are shown.

Article Snippet: E. coli cell pellet containing plasmid encoding mRNA eGFP (size 995 nt) was provided by Biomay AG and plasmid for saRNA mCHIK(S27) encoding chikungunya replicase and firefly luciferase (size 9787 nt) was provided by TRON (Mainz, Germany).

Techniques: Purification, W/O, Transfection, Expressing, Flow Cytometry, Fluorescence, Control, Luciferase

Journal: Molecular Therapy. Nucleic Acids

Article Title: Reverse-phase chromatography removes double-stranded RNA, fragments, and residual template to decrease immunogenicity and increase cell potency of mRNA and saRNA

doi: 10.1016/j.omtn.2025.102491

Figure Lengend Snippet: SDVB purification of mRNA and saRNA improves transgene expression in A549 cells, where IFNβ response limits expression (A) A549 cells were lipofected with 100 ng of mRNA purified with Oligo dT (“w/o SDVB”) or Oligo dT plus SDVB with linear gradient elution strategy (“linear-SDVB”) or Oligo dT plus step elution strategy (“step-SDVB”). Twenty-four hours after transfection, GFP expression was detected by flow cytometry. (B) Viability of cells was detected 48 h after lipofection and normalized to untreated cells. (C) IFNβ release into the supernatant was quantified by ELISA 6 and 24 h after transfection. (D) 10, 40, or 160 ng of saRNA without (“w/o SDVB”) or with (“+ SDVB”) SDVB purification was transfected into A549 cells. Luciferase expression was measured at 6, 24, 48, and 72 h after transfection and area under the curve was calculated to assess total transgene expression. (E) After 48 h, ATP levels were quantified and normalized to the levels of untreated cells to determine relative viability. (F) 6 and 24 h after lipofection, IFNβ levels in the supernatant were quantified by ELISA. Mean and standard error of the mean of three independent experiments, each done in technical triplicates, are shown. Statistical differences were calculated using two-sided unpaired t tests with p values lower than 0.05 considered as significant and classified into ∗: p < 0.05; ∗∗: p < 0.01; ∗∗∗: p < 0.001; ∗∗∗∗: p < 0.0001.

Article Snippet: E. coli cell pellet containing plasmid encoding mRNA eGFP (size 995 nt) was provided by Biomay AG and plasmid for saRNA mCHIK(S27) encoding chikungunya replicase and firefly luciferase (size 9787 nt) was provided by TRON (Mainz, Germany).

Techniques: Purification, Expressing, W/O, Transfection, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Luciferase